RANDOMIZED STUDY OF PHASE II / III OF PACLITAXEL + CARBOPLATINO WITH OR WITHOUT BEVACIZUMAB IN PATIENTS WITH ADVANCED PULMON CANCER OR METASTASIC NO SCAMOSO NSCLC.
Not Applicable
- Conditions
- C349-C349 Bronchus or lung, unspecifiedBronchus or lung, unspecified
- Registration Number
- PER-099-03
- Lead Sponsor
- EASTERN COOPERATIVE ONCOLOGY GROUP (ECOG),
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
not contemplated
Exclusion Criteria
not contemplated
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method